Cargando…

PDL1 expression and its correlation with outcomes in non-metastatic triple-negative breast cancer (TNBC)

PURPOSE: Triple-negative breast cancer (TNBC) has a poor outcome compared to other subtypes, even in those with early disease. Immune checkpoint inhibitors (ICIs) have been approved in metastatic diseases and are being tested as a neoadjuvant strategy also. The response to ICIs is largely determined...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghosh, Joydeep, Chatterjee, Meheli, Ganguly, Sandip, Datta, Anupurva, Biswas, Bivas, Mukherjee, Geetashree, Agarwal, Sanjit, Ahmed, Rosina, Chatterjee, Sanjoy, Dabkara, Deepak
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2021
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183644/ https://www.ncbi.nlm.nih.gov/pubmed/34158821 http://dx.doi.org/10.3332/ecancer.2021.1217

Ejemplares similares

Outcomes of metastatic neuroendocrine carcinoma of the gallbladder
por: Ghosh, Joydeep, et al.
Publicado: (2021)

Outcome of testicular non-seminomatous germ cell tumours: report from a tertiary cancer centre in eastern India
por: Biswas, Bivas, et al.
Publicado: (2021)

Metastatic Gastric cancer: Real world scenario from a developing country
por: Ganguly, Sandip, et al.
Publicado: (2018)

Multidisciplinary management of ovarian germ cell tumours—a single institutional study from India
por: Ganguly, Sandip, et al.
Publicado: (2021)

Metachronous muscle metastasis in a case of metastatic gallbladder cancer with TP35 gene mutation: A rare case report
por: Ghosh, Joydeep, et al.
Publicado: (2019)

Perspective of Oncology Patients During COVID-19 Pandemic: A Prospective Observational Study From India
por: Ghosh, Joydeep, et al.
Publicado: (2020)

Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
por: Ganguly, Sandip, et al.
Publicado: (2021)

Efficacy of cyclin-dependent kinase 4/6 inhibitors in patients with metastatic hormone positive breast cancer: a single institutional study from India
por: Ganguly, Sandip, et al.
Publicado: (2022)

Clinicopathological characteristics and treatment outcome in small cell lung cancer: A single institutional experience from India
por: Ganguly, Sandip, et al.
Publicado: (2020)

Multimodality treatment outcome in patients with primary malignant mediastinal germ cell tumor in adults
por: Biswas, Bivas, et al.
Publicado: (2020)

Outcome of COVID-19 in Solid Organ Malignancies: Experience From a Tertiary Cancer Center in Eastern India
por: Roy, Somnath, et al.
Publicado: (2021)

Not so ‘rare’—an example of malignant melanoma in India: report from a tertiary cancer centre
por: Biswas, Bivas, et al.
Publicado: (2021)

First-line Rucaparib Plus Bevacizumab Maintenance Completed One-Year in Germline BRCA1-Mutated Advanced Ovarian Cancer
por: Roy, Somnath, et al.
Publicado: (2022)

Effect of non-sentinel metastasis on adjuvant treatment decisions and survival in Z0011 eligible non-screened detected breast cancer population
por: Agrawal, Sanjit Kumar, et al.
Publicado: (2021)

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
por: Kumar, Sunny, et al.
Publicado: (2022)

Immunohistochemistry Heterogeneity in Reported Breast Cancer Demographics From India: Triple-Negative Breast Cancer Rates Could Be Lower Than Suggested in Pooled Meta-Analysis
por: Chatterjee, Sanjoy, et al.
Publicado: (2016)

Stigma Perceived by Women Following Surgery for Breast Cancer
por: Tripathi, Lopamudra, et al.
Publicado: (2017)

Oncologic safety of breast conservation following NACT in women with locally advanced breast cancer
por: Agrawal, Sanjit Kumar, et al.
Publicado: (2023)

NADPH Selective Depletion Nanomedicine‐Mediated Radio‐Immunometabolism Regulation for Strengthening Anti‐PDL1 Therapy against TNBC
por: Wang, Ying, et al.
Publicado: (2022)

[(89)Zr]-Atezolizumab-PET Imaging Reveals Longitudinal Alterations in PDL1 during Therapy in TNBC Preclinical Models
por: Massicano, Adriana V. F., et al.
Publicado: (2023)

Neural Functions Play Different Roles in Triple Negative Breast Cancer (TNBC) and non-TNBC
por: Tan, Renbo, et al.
Publicado: (2020)

Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects
por: Pushpam, Deepam, et al.
Publicado: (2020)

The fate of chemoresistance in triple negative breast cancer (TNBC)
por: O’Reilly, Elma A., et al.
Publicado: (2015)

Overexpression of CD73 is associated with recurrence and poor prognosis of gingivobuccal oral cancer as revealed by transcriptome and deep immune profiling of paired tumor and margin tissues
por: Chatterjee, Ankita, et al.
Publicado: (2023)

The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC)
por: Narrandes, Shavira, et al.
Publicado: (2018)

Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators?
por: Chatterjee, Sanjoy, et al.
Publicado: (2015)

Psycho-oncology service provisions for hospitalised cancer patients before and during the COVID-19 pandemic in an oncology centre in eastern India
por: Mukherjee, Arnab, et al.
Publicado: (2021)

Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro
por: Choi, Hoon Sik, et al.
Publicado: (2021)

Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
por: Lee, Jieun
Publicado: (2023)

Defining triple‐negative breast cancer with neuroendocrine differentiation (TNBC‐NED)
por: Hacking, Sean M, et al.
Publicado: (2023)

Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy
por: Kim, Sanghwa, et al.
Publicado: (2016)

Interleukin-3-Receptor-α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target
por: Koni, Malvina, et al.
Publicado: (2022)

Metastatic Primary Neuroendocrine Tumor of Ovary—A Rare Presentation
por: Saha, Sanghamitra, et al.
Publicado: (2022)

Epigenetic regulation of triple negative breast cancer (TNBC) by TGF-β signaling
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2021)

Recurrent triple-negative breast cancer (TNBC) tissues contain a higher amount of phosphatidylcholine (32:1) than non-recurrent TNBC tissues
por: Hosokawa, Yuko, et al.
Publicado: (2017)

Synthesis of Novel Peptide Dendrimers PDL-GB2 and PDL-G2
por: Yunzhu, Lin, et al.
Publicado: (2015)

Towards an immunoscore for triple negative breast cancer (TNBC): lymphocytic infiltrate predicts outcome
por: Adams, Sylvia, et al.
Publicado: (2013)

Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice
por: Schneeweiss, Andreas, et al.
Publicado: (2019)

Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)
por: Chaudhuri, Aiswarya, et al.
Publicado: (2022)

Tissue Selection for PD-L1 Testing in Triple Negative Breast Cancer (TNBC)
por: Dobritoiu, Florin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k4vh74h0oed0580ibmp3jqia5b